Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD.

ABSTRACT:

Purpose

Anti-vascular endothelial growth factor (anti-VEGF) drugs have dramatically improved the treatment of neovascular AMD. In pivotal studies, almost 90% of patients maintain vision, with approximately 30% showing significant improvement. Despite these successes, 10% to 15% of patients continue to lose vision, even with treatment. It has been reported that variants in some AMD-associated genes influence treatment outcome. This study showed an association of treatment outcome with variants in the apolipoprotein E (APOE) gene.

Methods

One hundred ninety-two patients receiving anti-VEGF treatment for subfoveal choroidal neovascularization secondary to AMD were enrolled. Information on demographics, lesion characteristics, delay until treatment, visual acuity (VA), and numbe

SUBMITTER: Wickremasinghe SS 

PROVIDER: S-EPMC3175959 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature